Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, May 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals ...

Children accounted for 4.2% of the scans. The researchers excluded tests in the patient's last year of life because it was unlikely to lead to cancer. Future cancers from radiation exposure Adults ...